Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
International multicenter open-label single-arm confidence-interval-estimation based Phase II
clinical trial, aiming to estimate a plausible range of the proportion of patients
experiencing efficacy failure in the population, to provide evidence for efficacy and safety
of the induction regimen with rATG and infliximab and a go/no go rule for further clinical
development.